vs
Side-by-side financial comparison of FIRSTSUN CAPITAL BANCORP (FSUN) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $110.0M, roughly 1.2× FIRSTSUN CAPITAL BANCORP). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 6.9%).
FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
FSUN vs TVTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $110.0M | $129.7M |
| Net Profit | $21.6M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | — | -25.0% |
| Net Margin | 19.6% | — |
| Revenue YoY | — | 73.4% |
| Net Profit YoY | -8.4% | — |
| EPS (diluted) | $0.76 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.0M | — | ||
| Q4 25 | $110.2M | $129.7M | ||
| Q3 25 | $107.3M | $164.9M | ||
| Q2 25 | $105.6M | $114.4M | ||
| Q1 25 | $96.2M | $81.7M | ||
| Q4 24 | $98.7M | $74.8M | ||
| Q3 24 | $98.2M | $62.9M | ||
| Q2 24 | $96.2M | $54.1M |
| Q1 26 | $21.6M | — | ||
| Q4 25 | $24.8M | — | ||
| Q3 25 | $23.2M | $25.7M | ||
| Q2 25 | $26.4M | $-12.8M | ||
| Q1 25 | $23.6M | $-41.2M | ||
| Q4 24 | $16.4M | — | ||
| Q3 24 | $22.4M | $-54.8M | ||
| Q2 24 | $24.6M | $-70.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% |
| Q1 26 | — | — | ||
| Q4 25 | 29.0% | -25.0% | ||
| Q3 25 | 26.4% | 15.1% | ||
| Q2 25 | 31.2% | -11.1% | ||
| Q1 25 | 30.9% | -52.2% | ||
| Q4 24 | 20.4% | -81.2% | ||
| Q3 24 | 29.1% | -89.3% | ||
| Q2 24 | 32.3% | -125.1% |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 21.6% | 15.6% | ||
| Q2 25 | 25.0% | -11.1% | ||
| Q1 25 | 24.5% | -50.4% | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 22.8% | -87.1% | ||
| Q2 24 | 25.5% | -130.1% |
| Q1 26 | $0.76 | — | ||
| Q4 25 | $0.89 | $0.04 | ||
| Q3 25 | $0.82 | $0.28 | ||
| Q2 25 | $0.93 | $-0.14 | ||
| Q1 25 | $0.83 | $-0.47 | ||
| Q4 24 | $0.57 | $-0.71 | ||
| Q3 24 | $0.79 | $-0.70 | ||
| Q2 24 | $0.88 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $413.7M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $114.8M |
| Total Assets | $8.6B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $413.7M | — | ||
| Q4 25 | $652.6M | $93.0M | ||
| Q3 25 | $659.9M | $110.9M | ||
| Q2 25 | $785.1M | $75.2M | ||
| Q1 25 | $621.4M | $61.9M | ||
| Q4 24 | $615.9M | $58.5M | ||
| Q3 24 | $573.7M | $36.4M | ||
| Q2 24 | $535.8M | $32.3M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $114.8M | ||
| Q3 25 | $1.1B | $73.6M | ||
| Q2 25 | $1.1B | $32.7M | ||
| Q1 25 | $1.1B | $32.8M | ||
| Q4 24 | $1.0B | $59.1M | ||
| Q3 24 | $1.0B | $-30.5M | ||
| Q2 24 | $996.6M | $15.1M |
| Q1 26 | $8.6B | — | ||
| Q4 25 | $8.5B | $605.2M | ||
| Q3 25 | $8.5B | $538.6M | ||
| Q2 25 | $8.4B | $555.3M | ||
| Q1 25 | $8.2B | $548.8M | ||
| Q4 24 | $8.1B | $594.1M | ||
| Q3 24 | $8.1B | $504.4M | ||
| Q2 24 | $8.0B | $551.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $111.5M | $60.7M | ||
| Q3 25 | $49.4M | $14.3M | ||
| Q2 25 | $15.0M | $5.0M | ||
| Q1 25 | $26.4M | $-42.2M | ||
| Q4 24 | $101.1M | $-35.7M | ||
| Q3 24 | $48.1M | $-42.5M | ||
| Q2 24 | $20.9M | $-40.2M |
| Q1 26 | — | — | ||
| Q4 25 | $104.0M | — | ||
| Q3 25 | $47.6M | $14.2M | ||
| Q2 25 | $13.0M | — | ||
| Q1 25 | $24.3M | — | ||
| Q4 24 | $95.7M | — | ||
| Q3 24 | $47.1M | — | ||
| Q2 24 | $19.9M | $-40.3M |
| Q1 26 | — | — | ||
| Q4 25 | 94.3% | — | ||
| Q3 25 | 44.4% | 8.6% | ||
| Q2 25 | 12.3% | — | ||
| Q1 25 | 25.3% | — | ||
| Q4 24 | 97.0% | — | ||
| Q3 24 | 47.9% | — | ||
| Q2 24 | 20.6% | -74.5% |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | — | ||
| Q3 25 | 1.6% | 0.1% | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | 1.1% | 0.0% | ||
| Q2 24 | 1.1% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 4.49× | — | ||
| Q3 25 | 2.13× | 0.56× | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 1.12× | — | ||
| Q4 24 | 6.18× | — | ||
| Q3 24 | 2.15× | — | ||
| Q2 24 | 0.85× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
